Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUQ: Pembrolizumab with or without Lenvatinib in Resectable Head and Neck Mucosal Melanoma
NCT03313206Phase 2Active, not recruiting
- Sponsor
- Gustave Roussy
- Start
- May 2018
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in head and neck mucosal melanoma (HNMM), sponsored by Gustave Roussy. Started May 2018; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
head and neck mucosal melanoma (HNMM)
Beyond the preview
Go deeper on NCT03313206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03313206.